COMMUNIQUÉS West-GlobeNewswire

Human Appeal’s Pot of Gold Film Comes to Amazon Prime Video
04/12/2025
BayView Entertainment Brings Groundbreaking Film to Global Streaming Audiences MISSION VIEJO, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Pot of Gold , the award winning powerful independent documentary set in the [...]
Coloplast A/S - Decisions at the Annual General Meeting 2025
04/12/2025
Today, 4 December 2025, Coloplast A/S held its Annual General Meeting, at which the following resolutions were adopted: The annual report for the financial year 2024/25 was approved. Distribution of year-end dividend of [...]
Chemed Corporation to Present at the BofA Securities 2025 Virtual Home Care Conference
04/12/2025
CINCINNATI, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Chemed Corporation (NYSE:CHE) today announced that it will present at the BofA Securities 2025 Virtual Home Care Conference on Tuesday, December 9, 2025, at 1:20 PM (ET). [...]
Foundation Health and Amazon Pharmacy Collaborate to Bring Real-Time Prescription Price Transparency to Patients
04/12/2025
API Integration Improves Medication Access and Empowers Patients with Expanded Fulfillment Options SAN FRANCISCO, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Foundation Health, a healthcare technology company that delivers AI- [...]
Philips reiterates timing of 2026 outlook
04/12/2025
December 4, 2025 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today reaffirmed that its 2026 outlook will be issued as planned on February 10, in line with the [...]
Tilray Releases the Ultimate 2025 Holiday Drink Gift Guide, Celebrating Seasonal Sips and Moments of Connection from Coast to Coast
04/12/2025
ATLANTA, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc., company (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), a global lifestyle and consumer packaged goods company at the forefront of the beverage, cannabis and [...]
Pliant Therapeutics Announces Interim Data from PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors
04/12/2025
One complete response and three partial responses observed in heavily pretreated ICI-secondary refractory patients in high dose cohorts Deep and durable ongoing responses with median time on treatment of 15 months [...]
Plus Therapeutics Highlights Three REYOBIQ™ Clinical Data Presentations at 2025 WFNOS/SNO Annual Meeting
04/12/2025
Cohort 1 data from multiple dose ReSPECT- Leptomeningeal Metastases (LM) trial showed no dosage limiting toxicity ReSPECT-Glioblastoma (GBM) trial of REYOBIQ as a novel therapeutic for recurrent GBM demonstrated [...]
From Lab to Global Impact: Polyrizon's Journey to Potentially Redefining Next-Generation Nasal Protection
04/12/2025
Ra’anana, Israel , Dec. 04, 2025 (GLOBE NEWSWIRE) -- In an era where airborne threats like allergens and viruses disrupt daily life for millions, a small biotech innovator in Israel is quietly reshaping approaches to [...]
Lexeo Therapeutics to Host Virtual Key Opinion Leader Event at the 22nd Global Cardiovascular Clinical Trialists (CVCT) Forum
04/12/2025
NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced plans [...]
Neuphoria Responds to Lynx1’s Revised Indication of Interest at a Reduced Price and Premium
04/12/2025
Neuphoria Will Continue its Well-Planned Strategic Alternatives Review, Which has Garnered Significant Positive Interest Urges Stockholders to Vote “FOR” BOTH of Neuphoria’s Nominees on the WHITE Proxy Card BURLINGTON, [...]
Hyperion DeFi Announces Receipt of Kinetiq Airdrop, Partnership with Native Markets, and Purchase of 150,000 Additional HYPE
04/12/2025
Receives 1,918,478.78 KNTQ in the Token Generation Event Airdrop, Plus Right to Earn Additional Yield on 28,888 HYPE Staked by the Company Partnership with Native Markets to Support Hyperliquid-Aligned USDH Stablecoin [...]
Ajax Therapeutics Presents Preclinical Data on Differentiated Efficacy Profile of AJ1-11095, a First-in-Class Type II JAK2 Inhibitor, at the American Society of Hematology Annual Meeting
04/12/2025
– Data demonstrate superior efficacy compared to ruxolitinib, an approved type I JAK2 inhibitor, including reductions in mutant allele burden and bone marrow fibrosis, key markers of disease modification – – AJ1-11095 [...]
BTT Medical Institute Announces Unprecedented Case of Total Reversal of ALS through Re-engineering of the Nobel Prize-Winning Fever Therapy into a Brain-Guided, Artificial Intelligence-Controlled ThermoFebrile Treatment
04/12/2025
First video-documented ALS reversal marks a new era for brain health achieved through noninvasive computerized brain-temperature modulation, confirmed by electrophysiological, molecular, and anatomical evidence MIAMI, [...]
Aclarion Announces Publication of Nociscan Article in Special Pain Issue of the International Journal of Spine Surgery (IJSS)
04/12/2025
Featured article strengthens growing body of clinical evidence for Nociscan by highlighting a successful case study Special Pain issue features breakthrough innovations shaping the future of spine care IJSS publishes [...]
Enlivex Management to Host Fireside Chat on December 11 to Discuss RAIN Token Strategy and Allocetra Clinical Development
04/12/2025
Nes-Ziona, Israel, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, “Enlivex” or “the Company”), today announced that it will host a virtual fireside chat on Thursday, December 11, 2025 at 11: [...]
Beghou Adds New Partners to Advance Integrated, Experience-Driven Commercialization in Life Sciences
04/12/2025
New additions enable clients to better connect pre-launch strategy through in-market execution—aligning intelligence and teams to drive effective launches and more cohesive customer engagement EVANSTON, Ill., Dec. 04, [...]
Remedy Plan Therapeutics to Present Results from Phase 1 Healthy Volunteer Study of NAMPT Inhibitor RPT1G and Other Progress at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition
04/12/2025
NAMPT inhibitor RPT1G demonstrated favorable safety and significant target engagement in first-in-human study Company to present Trial in Progress design from ongoing Phase 1 study of RPT1G in patients with advanced [...]
ViroMissile Appoints Mark Bertagnolli as Chief Operating Officer
04/12/2025
SAN DIEGO, Dec. 04, 2025 (GLOBE NEWSWIRE) -- ViroMissile , Inc., a cancer immunotherapy company pioneering the IDOV™ (Intravenously Deliverable Oncolytic Virus) platform, today announced the appointment of Mark [...]

Pages